H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.

CEO

Mr. Charl van Zyl

Employees

5000

Country

Denmark

ISIN

DK0061804770

WKN

000A3DMBV

Listings

0 Comments

Share your thoughts

FAQ

What is H. Lundbeck AS stock price today?▼

The current price of HLUN-B.CO is kr44.12 DKK — it has decreased by -0.59% in the past 24 hours. Watch H. Lundbeck AS stock price performance more closely on the chart.

What is H. Lundbeck AS stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Copenhagen Exchange exchange H. Lundbeck AS stocks are traded under the ticker HLUN-B.CO.

Is H. Lundbeck AS stock price growing?▼

HLUN-B.CO stock has risen by +6.52% compared to the previous week, the month change is a +6.26% rise, over the last year H. Lundbeck AS has showed a +6.47% increase.

What is H. Lundbeck AS market cap?▼

Today H. Lundbeck AS has the market capitalization of 10.68M

What is H. Lundbeck AS revenue for the last year?▼

H. Lundbeck AS revenue for the last year amounts to 24.63B DKK.

What is H. Lundbeck AS net income for the last year?▼

HLUN-B.CO net income for the last year is 3.19B DKK.

Does H. Lundbeck AS pay dividends?▼

Yes, HLUN-B.CO dividends are paid annual. The last dividend per share was 1.15 DKK. As of today, Dividend Yield (FWD)% is 2.61%.

How many employees does H. Lundbeck AS have?▼

As of September 06, 2026, the company has 5,000 employees.

In which sector is H. Lundbeck AS located?▼

H. Lundbeck AS operates in the Health & Wellness sector.

When did H. Lundbeck AS complete a stock split?▼

H. Lundbeck AS has not had any recent stock splits.

Where is H. Lundbeck AS headquartered?▼

H. Lundbeck AS is headquartered in Valby, Denmark.